BI1 Cost Reduction For A Health System Through Decreasing Number Of Eligible Patients For Biological Therapy In Patients With Rheumatoid Arthritis Using The Treat To Target Recommendations  by Santos-Moreno, P et al.
A808  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 8 0 5 – A 8 8 1  
system settings, reimbursement, HTA bodies and evaluation, evidence require-
ments, procurement process, value perception, and key trends and opportunities. 
This data was gathered through a partnership between Pharmerit and Ethicon Inc. A 
targeted literature review was conducted to collect information regarding these top-
ics. If gaps in the knowledge were identified after this review, interviews with local 
affiliates were conducted. Results: Through our methodology and analysis, the 
following results were identified. Brazil is growing and enjoys the largest economy 
and most attractive medical device market in Latin America growing 13.6% (CAGR) 
over the next decade. Health expenditure is valued at US$502 per capita. Brazil has 
200 Million people in the public sector, and 51 Million of those also have private 
insurance. New laws promote the development and purchasing of national products. 
Both the public and private sectors are regulated by the Ministry of Health (MoH) and 
ANVISA for premarket regulatory approval. Pricing is negotiated through tenders 
and purchasing negotiation, and differ by region. At this time Medical Devices do not 
have price regulation, but in 2015 a working group was created by the MoH in order 
to evaluate and regulate medical devices’ prices. HTA has grown rapidly leading to 
constrictions in adoption of new technologies and market access. New guidelines 
were prepared specifically for medical devices (HTA by CONITEC) in order to promote 
a better evaluation for medical devices.
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BI1
COST REDUCTION FOR A HEAlTH SySTEM THROUGH DECREASING NUMBER 
OF ElIGIBlE PATIENTS FOR BIOlOGICAl THERAPy IN PATIENTS WITH 
RHEUMATOID ARTHRITIS USING THE TREAT TO TARGET RECOMMENDATIONS
Santos-Moreno P, Saavedra-Martínez G, Bello-Gualtero J, Gómez-Mora D
Biomab, Centro de Artritis Reumatoide, Bogota, Colombia
Objectives: Biological therapy is a major therapeutic tool to prevent clinical and 
radiological progression of rheumatoid arthritis (RA), however due to the high 
cost of it is not possible to use extensively in Colombia. The aim of this study 
was to describe the reduction in Disease Activity Score 28 (DAS28) in patients 
with moderate-severe disease activity (MDA/SDA), by using strictly a Treat to 
Target (T2T) strategy for 24 and subsequently cost-savings obtained. MethOds: 
A descriptive cross-sectional study was performed. Records of patients with mod-
erate or severe disease activity (MDA/SDA) were reviewed; patients were consid-
ered potential candidates for biologic therapies and were followed-up under T2T 
standards. The aim of the study was to look at what percentage of patients who 
were in MDA/SDA disease activity reached a remission/low disease activity (Rem/
LDA) status. Descriptive epidemiology, the medians were analyzed using t-Student 
and disease activity was analyzed using Pearson´s statistics. Were analyzed cost-
savings obtained through decreasing the number of eligible patients for biological 
therapy. Results: 622 patients were included in this study, 453 (72.8%) women 
and 169 (27.2%) men. These patients came in moderate or severe disease activity 
with DAS28 3.5 in average; at 24 months with T2T strategy using only conventional 
DMARS 467 patients (75.1%) got remission/low disease activity status with a DAS28 
2.6 in average. The costs of biological therapy finishing 2014 on average was 16.595 
US dollars/year/patient, and for 467 patients amount in projected costs-savings of 
preventing use of biologics was approximately 5’824.849 US dollars/year, ranging 
between the cheaper biological and the most expensive (2’975.228 and 7’749.865 
US dollars/year) respectively. cOnclusiOns: The results of study showed that 
is possible to decrease disease activity and obtain a significant cost-reduction in 
RA by using only conventional DMARDs in a model with defined therapeutic goals 
like T2T and optimizing a multidisciplinary approach.
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TREATMENT PATTERNS AND BUDGETARy IMPACT OF CHEMOTHERAPy DRUGS 
IN A BRAzIlIAN PRIvATE HEAlTH PlAN (PHP)
Nishikawa AM1, Castro AP1, Alves AF1, Medina P1, Clark LG2
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil
Objectives: According to GLOBOSCAN 2012 and WHO, 14.1 million new cancer 
cases and 8.2 million deaths occurred worldwide in 2012. In Brazil, the incidence of 
the disease is also increasing as population ages, with 576,000 new cases of cancer 
expected in 2015. Despite the significant impact of disease and need for monitor-
ing and prevention, epidemiological and economic data that would help decision 
markers to evaluate unmet needs are still scarce. This study aims to evaluate the epi-
demiological aspects; economic impact and treatment patterns in a private health 
insurance plan with approximately 150,000 lives. MethOds: We retrieved data from 
Evidências-Kantar Health private market administrative claims database from June 
2012 to June 2013. After patient de-identification, data on diagnosis, type of drug, and 
line-of-treatment were collected. All ICDs and treatment patterns were reviewed by 
an oncologist. Health economist specialists priced the treatments (ex-factory price) 
in order to assess the budgetary impact. Only oncologic drug costs were considered 
– antiemetics, corticosteroids and equipment were not included). Exchange rate was 
1USD= 3.25BRL. Results: A total of 150 new cases of cancer were retrieved from the 
database. Median age was 59.5years (3 – 89) and body surface 1.775 m2 (0.72 – 2.3). 
The five most prevalent cancers were breast (19%), colon (15%), prostate (11%), non-
Hodgkin’s lymphoma (7%) and lung neoplasm (5%). The budget impact for cancer 
treatments was USD 1,464,958, (most impacting diseases: USD436,908 for breast, 
USD428,90 for colorectal and USD177,131 for non-Hodgkin lymphoma). Considering 
the average cost per patient treated, kidney (USD27,970), colon (USD19,495) and 
brain cancer (USD17,809) were the most expensive ones. Treatment pattern will be 
described in details in tables. cOnclusiOns: The increasing incidence of cancer 
and its costly treatments are significantly affecting the economic sustainability of 
the healthcare sector. This study maps the most prevalent and costly cancer treat-
ments under a private insurance perspective in Brazil.
was done. Results: TLR Avoided probability with DCB was 0,856 vs. 0,600 for PTA. 
DCB total cost was R$4.468 vs. R$3.737 for PTA. The ICER was R$2.856. In univariate 
sensitivity the ICER the total DCB cost was tested from -10% to +10%, obtaining ICER 
values that were from R$2.075 to R$3.637. In the Probabilistic Sensitivity analysis, 
it was a 24% probability for DCB to be dominant or cost-saving, and 98,3% of been 
under 3 GDP per Capita for Brazil. cOnclusiOns: DCB showed a 98,3% probability 
of been cost-effectiveness when compared to PTA and a 24% probability of been 
cost-saving.
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PR2
COMPETITION AND STRATEGIC REGUlATION IN THE ARGENTINE 
PHARMACEUTICAl MARkET: A COMPARATIvE STUDy OF SIx THERAPEUTIC 
ClASSES
Maceira D, Palacios A
Center for the Study of State and Society (CEDES), Buenos Aires, Argentina
Objectives: To analyze how main determinants of competition in six therapeutic 
target groups -analgesics, tranquilizers, peptic ulcer treatment, cholesterol treat-
ment, benign prostatic hypertrophy and ACE inhibitors- were affected by regula-
tions and drug policies implemented at national level during the last decade in 
the pharmaceutical market in Argentina. MethOds: The database corresponds 
to the annual information on retail sales in the Argentine pharmaceutical sector 
generated by IMS for the period 2005-2012. The estimation strategy takes the form 
of econometric models of ordinary least squares with year fixed effects and robust 
standard errors. The dependent variables explain the market shares of each product/
brand per therapeutic class, explained by prices, participant active principles, and 
a set of variables capturing product differentiation mechanisms implemented by 
pharmaceutical firms. Each therapeutic class’ regression was exposed to a vector of 
variables capturing the structure of the regulatory framework. Results: In general, 
prices do not show to be significant determinants of market shares, unlike factors 
associated with mechanisms of product differentiation do, proving they facilitate 
the development of brand loyalty and adherence, even with relatively higher prices. 
On the other hand, the inclusion of new active principles in the Compulsory Health 
Program (CHP) will act as a boost for priority prescriptions, while the production 
of generic medicines increases competition, reducing market shares. In addition, 
the impact of these policies rests heavily on the structure of competition in each 
therapeutic class. cOnclusiOns: The main health policy recommendations sug-
gest: the need to develop new areas of collaboration with the pharmaceutical sector, 
enhancing competition in markets with higher levels of concentration, facilitating 
the evaluation of policies on generic medicines, and successfully regularizing the 
structure of drugs and products available through the CHP.
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POTENTIAl PUBlIC RESOURCE SAvINGS IN BRAzIl: THE SOMATROPIN CASE
Lemos LL1, Silva MR1, Santos JB2, Costa JD 1, Gomes RM1, Nascimento RC2, Almeida AM3, 
Guerra Júnior AA2
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Objectives: Somatropin is provided in 4 and 12IU presentations by the Brazilian 
Unified Health System (SUS) for the treatment of Hypopituitarism (HP) and Turner 
Syndrome (TS). Other presentations are available in the market and are believed 
to provide a less costly treatment and/or less somatropin waste. MethOds: The 
registered medicines were obtained from the National Health Surveillance Agency 
(ANVISA) and their stability from package inserts. Monthly consumption and wast-
age analysis were estimated using the dose of somatropin for each disease and 
the average body weight of Minas Gerais State patients. Costs were estimated con-
sidering the Maximum Price of Sale to the Government from ANVISA. Results: 
Seventeen presentations (seven brands) of somatropin are available in the market 
and those with 28 days stability are not available in SUS. In general, medicines 
provided by SUS showed higher prices per IU. Immediate-use somatropin (4IU) 
showed the highest wastage and the highest cost estimates for both diseases. For 
HP, somatropin wastage of 4 and 12IU presentations was lower than that of the 
others available in the market. Regarding costs, they emerged in the fifth position 
of lower average cost for children and in the first and fifth positions for minimum 
and maximum doses for adults, respectively. For TS, monthly somatropin wast-
age was of 2.08-2.65IU for 4IU (7-14 days stability), slightly lower than that of 12 
to 18IU presentations. Medicines provided by SUS appeared in the ninth position 
of lower average cost. cOnclusiOns: Medicines incorporated by SUS presented 
the highest IU prices among registered medicines. Less wastage with incorporated 
presentations did not translate into better costs results (presentations of 15, 16 
and 18IU had lower or similar cost). The purchase of somatropin should be made 
allowing the participation of presentations of up to 18IU, with 7 to 28 days stability, 
and considering price per IU.
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IMPACT OF MAjOR CHANGES TO THE BRAzIlIAN HEAlTH CARE SySTEM 
UTIlIzING THE HEAT MAPS PROjECT
Panish JM1, Junqueira Junior SM2, Cabra HA3, Hutzul T4, Hensen M5
1Ethicon, Somerville, NJ, USA, 2Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3Johnson 
& Johnson Medical, México, D.F., Mexico, 4Johnson & Johnson Medical Products, Markham, ON, 
Canada, 5Pharmerit BV, Rotterdam, The Netherlands
Objective: To describe and understand the effects of various changes to the 
Brazilian Healthcare System, including a new guideline to elaborate HTA studies for 
Medical Devices, governmental price regulations, and demographics. MethOd: The 
Heat Maps project provides information from 17 major health care systems around 
the world, including Brazil. The Heat Maps capture: an overview of the healthcare 
